Hybrid vector designs to control the delivery, fate and expression of transgenes

Journal of Gene Medicine

Volumn 2, Issue 6, 2000, Pages 395-408

  Lam, Paula Y P ^a,b   Breakefield, Xandra O ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Hybrid viral vector; Regulation and site of expression; Transgene expression

Indexed keywords

RECOMBINANT DNA;

ANIMAL; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; REVIEW; TRANSGENE; VIRUS;

ANIMALS; DNA, RECOMBINANT; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; TRANSGENES; VIRUSES;

EID: 0034328422     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-2254(200011/12)2:6<395::aid-jgm146>3.0.co;2-k     Document Type: Review

References (163)

1. Lieber A, He CY, Kirillova I, Kay MA. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J Virol 1996; 70: 8944-8960.
2. Russ AP, Friedel C, Grez M, von Melchner H. Self-deleting retrovirus vectors for gene therapy. J Virol 1996; 70: 4927-4932.
3. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A 1996; 93: 13565-13570.
4. Zhang L, Sankar U, Lampe DJ, Robertson HM, Graham FL. The Himar1 mariner transposase cloned in a recombinant adenovirus vector is functional in mammalian cells. Nucleic Acids Res 1998; 26: 3687-3693.
5. Spear MA, Herrlinger U, Rainov N, Pechan P, Weissleder R, Breakefield XO. Targeting gene therapy vectors to CNS malignancies. J Neurovirol 1998; 4: 133-147.
6. Wickham TJ. Targeting adenovirus. Gene Ther 2000; 7: 110-114.
7. Roizman B, Sears EA. Herpes simplex viruses and their replication. In Fields Virology, Fields BN, Knipe DM, Howley PM (eds). Lippincott-Raven: Philadelphia, PA, USA, 1996; 2231-2296.
8. Montgomery RI, Warner MS, Lum BJ, Spear PG. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 1996; 87: 427-436.
9. Fink DJ, DeLuca NA, Yamada M, Wolfe DP, Glorioso JC. Design and application of HSV vectors for neuroprotection. Gene Ther 2000; 7: 115-119.
10. Sodeik B, Ebersold MW, Helenius A. Microtubule-mediated transport of incoming herpes simplex virus 1 capsids to the nucleus. J Cell Biol 1997; 136: 1007-1021.
11. Bearer EL, Breakefield XO, Schuback D, Reese TS, LaVail JH. Retrograde axonal transport of herpes simplex virus: evidence for a single mechanism and a role for tegument. Proc Natl Acad Sci U S A 2000; 97: 8146-8150.
12. Roizman B, Batterson W. Herpes viruses and their replication. In Virology, Fields BN (ed.). Raven Press: New York, NY, USA, 1991; 497-526.
13. Laquerre S, Anderson DB, Stolz DB, Glorioso JC. Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. J Virol 1998; 72: 9683-9697.
14. Anderson DB, Laquerre S, Goins WF, Cohen JB, Glorioso JC. Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry. J Virol 2000; 74: 2481-2487.
15. Albritton LM, Tseng L, Scadden D, Cunningham JM. A putative murine ecotropic retrovirus receptor gene encodes a multiple membrane-spanning protein and confers susceptibility to virus infection. Cell 1989; 57: 659-666.
16. Miller DB, Edwards RM, Miller AD. Cloning of the cellular receptor for amphotropic murine retroviruses reveals homology to that for gibbon ape leukemia virus. Proc Natl Acad Sci U S A 1994; 91: 78.
17. Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S A 1993; 90: 8033-8037.
18. Schlegel R, Willingham MC, Pastan IH. Saturable binding sites for vesicular stomatitis virus on the surface of Vero cells. J Virol 1982; 43: 871-875.
19. Mastromarino P, Conti C, Goldoni P, Hauttecoeur B, Orsi N. Characterization of membrane components of the erythrocyte involved in vesicular stomatitis virus attachment and fusion at acidic pH. J Gen Virol 1987; 68: 2359-2369.
20. Ory DS, Neugeboren BA, Mulligan RC. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci U S A 1996; 93: 11400-11406.
21. Peng KW, Vile R, Cosset FL, Russell S. Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors. Gene Ther 1999; 6: 1552-1557.
22. Schnierle BS, Groner B. Retroviral targeted delivery. Gene Ther 1996; 3: 1069-1073.
23. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323.
24. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-319.
25. Ginsberg HS, Prince GA. The molecular basis of adenovirus pathogenesis. Infect Agents Dis 1994; 3: 1-8.
26. Nemerow GR, Stewart PL. Role of alpha(v) integrins in adenovirus cell entry and gene delivery. Microbiol Mol Biol Rev 1999; 63: 725-734.
27. Einfeld DA, Brough DE, Roelvink PW, Kovesdi I, Wickham TJ. Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base. J Virol 1999; 73: 9130-9136.
28. Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, Ruoslahti E. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 1998; 102: 430-437.
29. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72: 1438-1445.
30. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 1999; 5: 71-77.
31. Summerford C, Bartlett JS, Samulski RJ. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 1999; 5: 78-82.
32. Bartlett JS, Wilcher R, Samulski RJ. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol 2000; 74: 2777-2785.
33. Kotin RM, Linden RM, Berns KI. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J 1992; 11: 5071-5078.
34. Linden RM, Ward P, Giraud C, Winocour E, Berns KI. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A 1996; 93: 11288-11294.
35. Vincent-Lacaze N, Snyder RO, Gluzman R, Bohl D, Lagarde C, Danos O. Structure of adeno-associated virus vector DNA following transduction of the skeletal muscle. J Virol 1999; 73: 1949-1955.
36. Yang J, Zhou W, Zhang Y, Zidon T, Ritchie T, Engelhardt JF. Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. J Virol 1999; 73: 9468-9477.
37. Dutheil N, Shi F, Dupressoir T, Linden RM. Adeno-associated virus site-specifically integrates into a muscle-specific DNA region. Proc Natl Acad Sci U S A 2000; 97: 4862-4866.
38. Yang Q, Mamounas M, Yu G, et al. Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy. Hum Gene Ther 1998; 9: 1929-1937.
39. Bartlett JS, Kleinschmidt J, Boucher RC, Samulski RJ. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody. Nat Biotechnol 1999; 17: 181-186.
40. Boyce FM, Bucher NL. Baculovirus-mediated gene transfer into mammalian cells. Proc Natl Acad Sci U S A 1996; 93: 2348-2352.
41. Miller G. Epstein-Barr virus: biology, pathogenesis and medical aspects. In Virology (2nd edn), Fields BN, Knipe DM, Chanock RM (eds). Raven Press: New York, NY, USA, 1990; 1921-1958.
42. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985; 313: 812-815.
43. Leight ER, Sugden B. EBNA-1: a protein pivotal to latent infection by Epstein-Barr virus. Rev Med Virol 2000; 10: 83-100.
44. Shelling AN, Smith MG. Targeted integration of transfected and infected adeno-associated virus vectors containing the neomycin resistance gene. Gene Ther 1994; 1: 165-169.
45. Nakai H, Iwaki Y, Kay MA, Couto LB. Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver. J Virol 1999; 73: 5438-5447.
46. Rutledge EA, Russell DW. Adeno-associated virus vector integration junctions. J Virol 1997; 71: 8429-8436.
47. Smith RH, Kotin RM. An adeno-associated virus (AAV) initiator protein, Rep78, catalyzes the cleavage and ligation of single-stranded AAV ori DNA. J Virol 2000; 74: 2133-3129.
48. Weitzman MD, Kyostio SR, Kotin RM, Owens RA. Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc Nat Acad Sci U S A 1994; 91: 5808-5812.
49. Balague C, Kalla M, Zhang WW. Adeno-associated virus Rep78 protein and terminal repeats enhance integration of DNA sequences into the cellular genome. J Virol 1997; 71: 3299-3306.
50. Tan BT, Wu L, Berk AJ. An adenovirus-Epstein-Barr virus hybrid vector that stably transforms cultured cells with high efficiency. J Virol 1999; 73: 7582-7589.
51. Hartigan-O'Connor D, Amalfitano A, Chamberlain JS. Improved production of gutted adenovirus in cells expressing adenovirus preterminal protein and DNA polymerase. J Virol 1999; 73: 7835-7841.
52. Schiedner G, Morral N, Parks RJ, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998; 18: 180-183.
53. Wang S, Vos JM. A hybrid herpesvirus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo. J Virol 1996; 70: 8422-8430.
54. Spaete R, Frenkel N. The herpes virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell 1982; 30: 295-304.
55. Geller AI, Breakefield XO. A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons. Science 1988; 241: 1667-1669.
56. Fraefel C, Jacoby DR, Lage C, et al. Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors. Mol Med 1997; 3: 813-825.
57. Sena-Esteves M, Saeki Y, Camp SM, Chiocca EA, Breakefield XO. Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons. J Virol 1999; 73: 10426-10439.
58. Aboody KS, Brown A, Rainov N, et al. Foreign gene-expressing mouse and human neural stem cells display extensive tropism for pathology in the adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A, 2000; 97: 12846-12851.
59. Feng M, Jackson Jr WH, Goldman CK, et al. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nat Biotechnol 1997; 15: 866-870.
60. Yoshida Y, Emi N, Hamada H. VSV-G-pseudotyped retroviral packaging through adenovirus-mediated inducible gene expression. Biochem Biophys Res Commun 1997; 232: 379-382.
61. Duisit G, Salvetti A, Moullier P, Cosset FL. Functional characterization of adenoviral/retroviral chimeric vectors and their use for efficient screening of retroviral producer cell lines. Hum Gene Ther 1999; 10: 189-200.
62. Fisher KJ, Kelley WM, Burda JF, Wilson JM. A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome. Hum Gene Ther 1996; 7: 2079-2087.
63. Recchia A, Parks RJ, Lamartina S, et al. Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proc Natl Acad Sci U S A 1999; 96: 2615-2620.
64. Lieber A, Steinwaerder DS, Carlson CA, Kay MA. Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes. J Virol 1999; 73: 9314-9324.
65. Conway JE, Zolotukhin S, Muzyczka N, Hayward GS, Byrne BJ. Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap. J Virol 1997; 71: 8780-8789.
66. Johnston KM, Jacoby D, Pechan P, et al. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum Gene Ther 1997; 8: 359-370.
67. Constantini LC, Jacoby DR, Wang S, Fraefel C, Breakefield XO, Isacson O. Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors. Hum Gene Ther 1999; 10: 2481-2494.
68. Palombo F, Monciotti A, Recchia A, Cortese R, Ciliberto G, La Monica N. Site-specific integration in mammalian cells mediated by a new hybrid baculovirus-adeno-associated virus vector. J Virol 1998; 72: 5025-5034.
69. Sandig V, Hofmann C, Steinert S, Jennings G, Schlag P, Strauss M. Gene transfer into hepatocytes and human liver tissue by baculovirus vectors. Hum Gene Ther 1996; 20: 1937-1945.
70. Wahlfors JJ, Xanthopoulos KG, Morgan RA. Semliki Forest virus-mediated production of retroviral vector RNA in retroviral packaging cells. Hum Gene Ther 1997; 8: 2031-2041.
71. Wahlfors JJ, Morgan RA. Production of minigene-containing retroviral vectors using an alphavirus/retrovirus hybrid vector system. Hum Gene Ther 1999; 10: 1197-1206.
72. Holzer GW, Mayrhofer JA, Gritschenberger W, Dorner F, Falkner FG. Poxviral/retroviral chimeric vectors allow cytoplasmic production of transducing defective retroviral particles. Virology 1999; 253: 107-114.
73. Hodge JW, Schlom J. Comparative studies of a retrovirus versus a poxvirus vector in whole tumor-cell vaccines. Cancer Res 1999; 59: 5106-5111.
74. Orban PC, Chui D, Marth JD. Tissue-and site-specific DNA recombination in transgenic mice. Proc Natl Acad Sci U S A 1992; 89: 6861-6865.
75. Sauer B, Henderson N. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc Natl Acad Sci U S A 1988; 85: 5166-5170.
76. Thyagarajan B, Guimaraes MJ, Groth AC, Caols MP. Mammalian genomes contain active recombinase recognition sites. Gene 2000; 244: 47-54.
77. Rinaldi A, Marshall KR, Preston CM. A non-cytotoxic herpes simplex virus vector which expresses Cre recombinase directs efficient site specific recombination. Virus Res 1999; 65: 11-20.
78. Logvinoff C, Epstein AL. Genetic engineering of herpes simplex virus and vector genomes carrying loxP sites in cells expressing Cre recombinase. Virology 2000; 267: 102-110.
79. Akagi K, Sandig V, Vooijs M, et al. Cre-mediated somatic site-specific recombination in mice. Nucleic Acids Res 1997; 25: 1766-1773.
80. Scott SD, Marples B, Hendry JH, et al. A radiation-controlled molecular switch for use in gene therapy of cancer. Gene Ther 2000; 7: 1121-1125.
81. Schouten GJ, van Luenen HG, Verra NC, Valerio D, Plasterk RH. Transposon Tc1 of the nematode Caenorhabditis elegans jumps in human cells. Nucleic Acids Res 1998; 26: 3013-3017.
82. Ivics Z, Hackett PB, Plasterk RH, Izsvak Z. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 1997; 91: 501-510.
83. Zhang Y, Buchholz F, Muyrers JP, Stewart AF. A new logic for DNA engineering using recombination in Escherichia coli. Nat Genet 1998; 20: 123-128.
84. Grindley ND, Leschziner AE. DNA transposition: from a black box to a color monitor. Cell 1995; 83: 1063-1066.
85. Mizuuchi K. Polynucleotidyl transfer reactions in site-specific DNA recombination. Genes Cells 1997; 2: 1-12.
86. Plasterk RH. The Tc1/mariner transposon family. Curr Top Microbiol Immunol 1996; 204: 125-143.
87. Stone D, David A, Bolognani F, Loewstein PR, Castro MG. Viral vectors for gene delivery and gene therapy within the endocrine system. J Endocrinol 2000; 164: 103-118.
88. Luo G, Ivies Z, Izsvak Z, Bradley A. Chromosomal transposition of a Tc1/mariner-like element in mouse embryonic stem cells. Proc Natl Acad Sci U S A 1998; 95: 10769-10773.
89. Wegner M, Helftenbein E, Muller F, Meinecke M, Muller S, Grummt F. Identification of an amplification promoting DNA sequence from the hypotrichous ciliate Stylonychia lemnae. Nucleic Acids Res 1989; 17: 8783-8802.
90. Grimes B, Cooke H. Engineering mammalian chromosomes. Hum Mol Genet 1998; 7: 1635-1640.
91. Barry AE, Howman EV, Cancilla MR, Saffery R, Choo KH. Sequence analysis of an 80 kb human neocentromere. Hum Mol Genet 1999; 8: 217-227.
92. Ikeno M, Grimes B, Okazaki T, et al. Construction of YAC-based mammalian artificial chromosomes. Nat Biotechnol 1998; 16: 431-439.
93. du Sart D, Cancilla MR, Earle E, et al. A functional neocentromere formed through activation of a latent human centromere and consisting of non-alpha-satellite DNA. Nat Genet 1997; 16: 144-153.
94. Nielsen TO, Cossons NH, Zannis-Hadjopoulos M, Price GB. Circular YAC vectors containing short mammalian origin sequences are maintained under selection as HeLa episomes. J Cell Biochem 2000; 76: 674-685.
95. Jones PL, Veenstra GJ, Wade PA, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998; 19: 187-191.
96. Dai Y, Roman M, Naviaux RK, Verma IM. Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo. Proc Natl Acad Sci U S A 1992; 98: 10892-10895.
97. Hagstrom JN, Couto LB, Scallan C, et al. Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid. Blood 2000; 95: 2536-2542.
98. Tamiya T, Wei MX, Chase M, et al. Transgene inheritance and retroviral infection contribute to the efficiency of gene expression in solid tumors inoculated with retroviral vector producer cells. Gene Ther 1995; 2: 531-538.
99. Emerman M, Temin HM. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell 1984; 39: 449-467.
100. Vile R, Miller N, Chemajovsky Y, Hart I. A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes. Gene Ther 1994; 1: 307-316.
101. Artelt P, Grannemann R, Stocking C, Friel J, Bartsch J, Hauser H. The prokaryotic neomycin-resistance-encoding gene acts as a transcriptional silencer in eukaryotic cells. Gene 1991; 99: 249-254.
102. Attal J, Theron MC, Houdebine LM. The optimal use of IRES (internal ribosome entry site) in expression vectors. Genet Anal 1999; 15: 161-165.
103. Loeb JE, Cordier WS, Harris ME, Weitzman MD, Hope TJ. Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis virus posttranscriptional regulatory element: implications for gene therapy. Hum Gene Ther 1999; 10: 2295-2305.
104. Degon N, Tseng JL, Bensadoun JC, et al. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum Gene Ther 2000; 11: 179-190.
105. Morral N, O'Neal W, Zhou H, Langston C, Beaudet A. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. Hum Gene Ther 1997; 8: 1275-1286.
106. Kioussis D, Festenstein R. Locus control regions: overcoming heterochromatin-induced gene inactivation in mammals. Curr Opin Genet Dev 1997; 7: 614-619.
107. Plavec I, Papyannopoulou T, Maury C, Meyer F. A human beta-globin gene fused to the human beta-globin locus control region is expressed at high levels in erythroid cells of mice engrafted with retrovirus-transduced hematopoietic stem cells. Blood 1993; 81: 1384-1392.
108. Li Q, Harju S, Peterson KR. Locus control regions: coming of age at a decade plus. Trends Genet 1999; 15: 403-108.
109. Hoag H, Gore J, Barry D, Mueller C. Gene therapy expression vectors based on the clotting Factor IX promoter. Gene Ther 1999; 6: 1584-1589.
110. Pikaart MJ, Recillas-Targa F, Felsenfeld G. Loss of transcriptional activity of a transgene is accompanied by DNA methylation and histone deacetylation and is prevented by insulators. Genes Dev 1998; 12: 2852-2862.
111. Vassaux G, Hurst HC, Lemoine NR. Insulation of a conditionally expressed transgene in an adenoviral vector. Gene Ther 1999; 6: 1192-1197.
112. Steinwaerder DS, Lieber A. Insulation from viral transcriptional regulatory elements improves inducible transgene expression from adenovirus vectors in vitro and in vivo. Gene Ther 2000; 7: 556-567.
113. Rivera VM, Clackson T, Natesan S, et al. A humanized system for pharmacologic control of gene expression. Nat Med 1996; 2: 1028-1032.
114. Kalos M, Fournier RE. Position-independent transgene expression mediated by boundary elements from the apolipoprotein B chromatin domain. Mol Cell Biol 1995; 15: 198-207.
115. Makarova O, Gorneva G, Wu F, et al. Incorporation of nuclear matrix attachment regions into the herpes simplex virus type 1 genome does not induce long-term expression of a foreign gene during latency. Gene Ther 1999; 3: 829-833.
116. McKnight RA, Shamay A, Sankaran L, Wall RJ, Hennighausen L. Matrix-attachment regions can impart position-independent regulation of a tissue-specific gene in transgenic mice. Proc Natl Acad Sci U S A 1992; 89: 6943-6947.
117. Agarwal M, Austin TW, Morel F, Chen J, Bohnlein Ed, Playec I. Scaffold attachment region-mediated enhancement of retroviral expression in primary T cells. J Virol 1998; 72: 3720-3728.
118. Auten J, Agarwal M, Chen J, Sutton R, Plavec I. Effect of scaffold attachment region on transgene expression in retrovirus vector-transduced primary T cells and macrophages. Hum Gene Ther 1999; 10: 1389-1399.
119. Dang Q, Auten J, Plavec I. Human beta interferon scaffold attachment region inhibits de novo methylation and confers long-term, copy number-dependent expression to a retroviral vector. J Virol 2000; 74: 2671-2678.
120. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A 1992; 89: 5547-5551.
121. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995; 268: 1766-1769.
122. No D, Yao TP, Evans RM. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc Natl Acad Sci U S A 1996; 93: 3346-3351.
123. Wang Y, O'Malley Jr BW, Tsai SY, O'Malley BW. A regulatory system for use in gene transfer. Proc Natl Acad Sci U S A 1994; 91: 8180-8184.
124. Ho SN, Biggar SR, Spencer DM, Schreiber SL, Crabtree GR. Dimeric ligands define a role for transcriptional activation domains in reinitiation. Nature 1996; 382: 822-826.
125. Amara JF, Clackson T, Rivera VM, et al. A versatile synthetic dimerizer for the regulation of protein-protein interactions. Proc Natl Acad Sci U S A 1997; 94: 10618-10623.
126. Magari SR, Rivera VM, Iuliucci JD, Gilman M, Cerasoli Jr F. Pharmacologic control of a humanized gene therapy system implanted into nude mice. J Clin Invest 1997; 100: 2865-2872.
127. Clarkson T. Controlling mammalian gene expression with small molecules. Curr Opin Chem Biol 1997; 1: 210-218.
128. Sastry S, Ross BM. Probing the interaction of T7 RNA polymerase with promoter. Biochemistry 1999; 38: 4972-4981.
129. Zabner J, Fasbender AJ, Moninger T, Poellinger KA, Welsh MJ. Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem 1995; 270: 18997-189007.
130. Moss B, Elroy-Stein O, Mizukami T, Alexander WA, Fuerst TR. Product review. New mammalian expression vectors. Nature 1990; 348: 91-92.
131. Wyatt LS, Moss B, Rozenblatt S. Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology 1995; 210: 202-205.
132. van den Wollenberg DJ, Hoeben RC, van Ormondt H, van der Eb AJ. Insertion of the human cytomegalovirus enhancer into a myeloproliferative sarcoma virus long terminal repeat creates a high-expression retroviral vector. Gene 1994; 144: 237-241.
133. McBurney MW, Sutherland LC, Adra CN, Leclair B, Rudnicki MA, Jardin EK. The mouse Pgk-1 gene promoter contains an upstream activator sequence. Nucleic Acids Res 1991; 19: 5755-5761.
134. Kim DW, Uetsuki T, Kaziro Y, Yamaguchi N, Sugano S. Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. Gene 1990; 91: 217-223.
135. Dorsch-Hasler K, Keil GM, Weber F, Jasin M, Schaffner W, Koszinowski UH. A long and complex enhancer activates transcription of the gene coding for the highly abundant immediate early mRNA in murine cytomegalovirus. Proc Natl Acad Sci U S A 1985; 82: 8325-8329.
136. Diaz RM, Eisen T, Hart IR, Vile RG. Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma. J Virol 1998; 72: 789-795.
137. Jager U, Zhao Y, Porter CD. Endothelial cell-specific transcriptional targeting from a hybrid long terminal repeat retrovirus vector containing human prepro-endothelin-1 promoter sequences. J Virol 1999; 73: 9702-9709.
138. Li X, Eastman EM, Schwartz RJ, Draghia-Akli R. Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences. Nat Biotechnol 1999; 17: 241-245.
139. Marples S, Scott SD, Hendry JH, Embleton MJ, Lashford LS, Margison GP. Development of synthetic promoters for radiation-mediated gene therapy. Gene Ther 2000; 7: 511-517.
140. Jacobs A, Breakefield XO, Fraefel C. HSV-1 based vectors for gene therapy of neurological diseases and brain tumors. Part II. Vector systems and applications. Neoplasia 1999; 5: 402-416.
141. Kurihara H, Zama A, Tamura M, Takeda J, Sasaki T, Takeuchi T. Glioma/glioblastoma-specific adenoviral gene expression using the nestin gene regulator. Gene Ther 2000; 7: 686-693.
142. Brenner M, Kisseberth WC, Su Y, Besnard F, Messing A. GFAP promoter directs astrocyte-specific expression in transgenic mice. J Neurosci 1994; 14: 1030-1037.
143. Schwartz ML, Katagi C, Bruce J, Schlaepfer WW. Brain-specific enhancement of the mouse neurofilament heavy gene promoter in vitro. J Biol Chem 1994; 269: 13444-13450.
144. Charron G, Gur LG, Bazinet M, Julien JP. Multiple neuron-specific enhancers in the gene coding for the human neurofilament light chain. J Biol Chem 1995; 270: 30604-30610.
145. Forss-Petter S, Danielson PE, Catsicas S, et al. Transgenic mice expressing beta-galactosidase in mature neurons under neuron-specific enolase promoter control. Neuron 1990; 5: 187-197.
146. During MJ, Naefele JR, O'Malley KL, Geller AI. Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 1994; 266: 1399-1403.
147. Jin BK, Belloni M, Conti B, et al. Prolonged in vivo gene expression driven by a tyrosine hydroxylase promoter in a defective herpes simplex virus amplicon vector. Hum Gene Ther 1993; 7: 2015-2024.
148. Miyao Y, Shimizu K, Moriuchi S, et al. Selective expression of foreign genes in glioma cells: use of the mouse myelin basic protein gene promoter to direct toxic gene expression. J Neurosci Res 1993; 36: 472-479.
149. Adam MA, Ramesh N, Miller AD, Osborne WR. Internal initiation of translation in retroviral vectors carrying picorna-virus 5′ nontranslated regions. J Virol 1991; 65: 4985-4990.
150. Kraus J, Buchfelder M, Hollt V. Regulatory elements of the human proopiomelanocortin gene promoter. DNA Cell Biol 1993; 12: 527-536.
151. Haugen BR, McDermott MT, Gordon DF, Rupp CL, Wood WM, Ridgway EC. Determinants of thyrotrope-specific thyrotropin beta promoter activation. Cooperation of Pit-1 with another factor. J Biol Chem 1996; 271: 385-389.
152. Albarracin CT, Frosch MP, Chin WW. The gonadotropin-releasing hormone receptor gene promoter directs pituitary-specific oncogene expression in transgenic mice. Endocrinology 1999; 140: 2415-2421.
153. Mavria G, Jager U, Porter CD. Generation of a high titre retroviral vector for endothelial cell-specific gene expression in vivo. Gene Ther 2000; 7: 368-376.
154. Tilghman SM, Belayew A. Transcriptional control of the murine albumin/alpha-fetoprotein locus during development. Proc Natl Acad Scu U S A 1982; 79: 5254-5257.
155. Arbuthnot P, Bralet MP, Thomassin H, Danan JL, Brechot C, Ferry N. Hepatoma cell-specific expression of a retrovirally transferred gene is achieved by alpha-fetoprotein but not insulinlike growth factor II regulatory sequences. Hepatology 1995; 22: 1788-1796.
156. Lian JB, Stein GS, Stein JL, van Wijnen AJ. Osteocalcin gene promoter: unlocking the secrets for regulation of osteoblast growth and differentiation. J Cell Biochem 1998; 30-31: 62-72.
157. Sternberg EA, Spizz G, Perry WM, Vizard D, Weil T, Olson EN. Identification of upstream and intragenic regulatory elements that confer cell-type-restricted and differentiation-specific expression on the muscle creatine kinase gene. Mol Cell Biol 1988; 8: 2896-2909.
158. Leonard J, Peers B, Johnson T, Ferreri K, Lee S, Montminy MR. Characterization of somatostatin transactivating factor-1, a novel homeobox factor that stimulates somatostatin expression in pancreatic islet cells. Mol Endocrinol 1993; 7: 1275-1283.
159. Dematteo RP, McClane SJ, Fisher K, et al. Engineering tissue-specific expression of a recombinant adenovirus: selective transgene transcription in the pancreas using the amylase promoter. J Surg Res 1997; 72: 155-161.
160. Hussain MA, Lee J, Miller CP, Habener JF. POU domain transcription factor brain 4 confers pancreatic alpha-cell-specific expression of the proglucagon gene through interaction with a novel proximal promoter G1 element. Mol Cell Biol 1997; 17: 7186-7194.
161. Schrewe H, Thompson J, Bona M, et al. Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression. Mol Cell Biol 1990; 10: 2738-2748.
162. Latham JP, Searle PF, Mautner V, James ND. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res 2000; 60: 334-341.
163. Vile RG, Hart IR. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res 1993; 53: 962-967.